{"id":"fosaprepitant-for-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Hiccups"},{"rate":null,"effect":"Infusion site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fosaprepitant crosses the blood-brain barrier and is metabolized to aprepitant, which competitively antagonizes NK1 receptors. By blocking neurokinin-1 signaling, it prevents both the acute and delayed emetic responses triggered by chemotherapy. This mechanism is particularly effective for highly emetogenic chemotherapy regimens when combined with 5-HT3 antagonists and corticosteroids.","oneSentence":"Fosaprepitant is an intravenous prodrug that is rapidly converted to aprepitant, a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:52.656Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy"},{"name":"Prevention of postoperative nausea and vomiting (PONV)"}]},"trialDetails":[{"nctId":"NCT07482891","phase":"PHASE4","title":"An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 6th People's Hospital","startDate":"2026-03-10","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":200},{"nctId":"NCT07081256","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-01-03","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":665},{"nctId":"NCT06740812","phase":"PHASE4","title":"Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-05","conditions":"Nausea and Vomiting, Nausea, Vomiting","enrollment":212},{"nctId":"NCT07124195","phase":"PHASE3","title":"Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Xinxiang Medical College","startDate":"2025-08-10","conditions":"Malignant Solid Tumors, Moderate to High Emetogenic Chemotherapy (MEC/HEC) Drugs","enrollment":126},{"nctId":"NCT06200168","phase":"PHASE3","title":"Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2024-01-16","conditions":"Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting","enrollment":370},{"nctId":"NCT05773950","phase":"NA","title":"Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention","status":"ENROLLING_BY_INVITATION","sponsor":"Samsung Medical Center","startDate":"2023-08-18","conditions":"Postoperative Nausea and Vomiting, Gynecologic Surgical Procedures, Laparoscopy","enrollment":144},{"nctId":"NCT04054193","phase":"PHASE4","title":"Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-09-09","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":103},{"nctId":"NCT06427681","phase":"EARLY_PHASE1","title":"An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Zhuhai Beihai Biotech Co., Ltd","startDate":"2024-05","conditions":"Bioavailability","enrollment":40},{"nctId":"NCT05509634","phase":"PHASE3","title":"Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors","status":"COMPLETED","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","startDate":"2022-09-21","conditions":"Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy","enrollment":754},{"nctId":"NCT05755659","phase":"NA","title":"Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2022-07-15","conditions":"Neoplasms","enrollment":3000},{"nctId":"NCT02732015","phase":"PHASE2","title":"Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-10-12","conditions":"Locally Advanced Sarcoma","enrollment":37},{"nctId":"NCT01697579","phase":"PHASE2","title":"Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-13","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":240},{"nctId":"NCT02519842","phase":"PHASE3","title":"Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-14","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":75},{"nctId":"NCT00818259","phase":"PHASE1","title":"A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02-05","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":92},{"nctId":"NCT01594749","phase":"PHASE3","title":"Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-24","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":1015},{"nctId":"NCT01432015","phase":"PHASE4","title":"Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Gynecologic Oncology Associates","startDate":"2011-09","conditions":"Ovarian Cancer, Uterine Cancer","enrollment":20},{"nctId":"NCT02407600","phase":"PHASE2","title":"Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy","status":"UNKNOWN","sponsor":"Ajeet Gajra","startDate":"2015-04","conditions":"Non-small Cell Lung Cancer, Vomiting, Nausea","enrollment":150}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DYSPNOEA"},{"count":1,"reaction":"BLOOD PRESSURE INCREASED"},{"count":1,"reaction":"CHEST DISCOMFORT"},{"count":1,"reaction":"DIZZINESS"},{"count":1,"reaction":"ERYTHEMA"},{"count":1,"reaction":"FLUSHING"},{"count":1,"reaction":"HEART RATE INCREASED"},{"count":1,"reaction":"HYPERTENSION"},{"count":1,"reaction":"OFF LABEL USE"},{"count":1,"reaction":"PRODUCT PREPARATION ISSUE"}],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Fosaprepitant for Injection","genericName":"Fosaprepitant for Injection","companyName":"Montefiore Medical Center","companyId":"montefiore-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fosaprepitant is an intravenous prodrug that is rapidly converted to aprepitant, a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center. Used for Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, Prevention of postoperative nausea and vomiting (PONV).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}